+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Fostemsavir (GSK3684934) (ViiV Healthcare) Drug Overview 2019

  • PDF Icon


  • 15 Pages
  • June 2019
  • Region: Global
  • Citeline
  • ID: 4846139
Drug Overview
Fostemsavir (GSK3684934) (ViiV Healthcare), previously known as BMS-663068, is an oral prodrug of GSK2616713 (formerly BMS-626529). It is an attachment inhibitor which binds to the gp120 protein of HIV to prevent viral attachment to the host CD4+ T cells, which is necessary for entry into host cells. In December 2015, fostemsavir was acquired by ViiV Healthcare, which is now responsible for the development of the drug.

Fostemsavir is a novel oral attachment inhibitor being developed for use in multidrug-resistant patients, where there is significant unmet need for novel modes of action. Fostemsavir’s key differentiator over recently approved intravenous monoclonal antibody Trogarzo (ibalizumab; Theratechnologies/TaiMed Biologics) is its more convenient oral twice-daily dosing, which is expected to lower treatment costs for payers and patients. However, fostemsavir’s twice-daily dosing schedule is expected to preclude future progression to the earlier lines of therapy, where a plethora of more convenient once-daily regimens currently dominate.

Table of Contents

  • Drug Overview
  • Product Profiles
  • fostemsavir: HIV

Figure 1: The author's drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 2: The author's drug assessment summary of cabotegravir/rilpivirine for HIV
Table 1: Fostemsavir drug profile
Table 2: Late-phase trials of fostemsavir for HIV
Table 3: Fostemsavir for HIV – SWOT analysis